Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies

RegulatoryRelutrigineNeutral

AI Analysis

Summary

Praxis Precision Medicines announced an extension period for Relutrigine in the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies. Limited details are available in the headline regarding the nature or implications of this extension.

Outcome Details

Extension period announced

Importance:3/10

Sentiment:

0.00

rare diseaseepilepsyregulatoryCNS

Related Companies

$PRAX

Read the original article

Published by yahoo_finance on June 29, 2026 8:30 PM

Read Original